Ripple Therapeutics Enters Collaboration With Bausch + Lomb

Ripple, Bausch + Lomb partner on drug delivery implants

Ripple Therapeutics announced today that it entered into a deal with a Bausch + Lomb affiliate related to drug delivery technology. Toronto-based Ripple develops a patented technology platform based on drugs chemically engineered into controlled-release pharmaceuticals without the use of polymers. The proprietary prodrugs undergo surface erosion to give zero-order release kinetics. They are highly engineerable to tailor to both drug dose and dur…

Ripple Therapeutics Enters Collaboration With Bausch + Lomb

Ripple Therapeutics, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, announced earlier this year that it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers, wh…

Ripple enters into a collaboration with Bausch + Lomb - BioTuesdays

Closely held Ripple Therapeutics has announced that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb (NYSE/TSX: BLCO). Under the terms of the agreement, Bausch + Lomb will fund the early-stage feasibility and preclinical evaluation of the target molecule and will have the option to license any formulations being evaluated under the program for additional financial conside…